<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The association of anticardiolipin antibodies (aCL) with unexplained vascular occlusive disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) is well known </plain></SENT>
<SENT sid="1" pm="."><plain>We reviewed the records of 102 consecutive patients seen over a 9 months period who had positive IgG or IgM aCL to determine the frequency and types of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> in this unselected group of patients </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> was detectable in 17 of 67 (25%) patients tested </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> occurred in 80 of 102 (78%) aCL-positive patients comprised of 17 (16.7%) with systemic venous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> or <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>; 27 (26.5%) with cerebral <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>: 11 (10.8%) with systemic arterial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>; 3 (2.9%) with coronary <z:mp ids='MP_0005048'>thrombosis</z:mp>; and 5 (4.9%) with visceral venous or arterial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 19 obstetric patients with positive aCL, 17 (89%) had at least one unexplained fetal loss and 8 of the 17 (47%) had multiple or recurrent fetal losses </plain></SENT>
<SENT sid="5" pm="."><plain>Twelve (11.7%) of the 102 patients met the ACR criteria for <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, 12 (11.7%) patients were identified as nonSLE or <z:e sem="disease" ids="C0409999" disease_type="Disease or Syndrome" abbrv="">undifferentiated connective tissue disease</z:e> (CTD) </plain></SENT>
<SENT sid="7" pm="."><plain>The remaining 78 (76%) had no known underlying disease (<z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e>) </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that IgG and IgM aCL with or without <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> are associated with diverse types of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> but cerebral <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> appears predominant </plain></SENT>
<SENT sid="9" pm="."><plain>aCL-associated unexplained <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> occurs frequently in patients without evidence of CTD-65 of 80 (81%) in our series </plain></SENT>
<SENT sid="10" pm="."><plain>Testing for aCL is essential for identifying patients with unexplained <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>, and it should be performed in prospective clinical studies of such patients to better define the pathogenic role of aCL in the natural history of unexplained <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> </plain></SENT>
</text></document>